Articles From: Tetra Tech Announces Planned Dates for Fourth Quarter 2014 Results and Conference Call to Teva Appoints Yitzhak Peterburg as Chairman


Tetra Tech, Inc. (NASDAQ: TTEK) today announced the planned dates for its fourth quarter 2014 results and conference call.
Sign-up for Tetra Tech Announces Planned Dates for Fourth Quarter 2014 Results and Conference Call investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) today is providing an update on its previously announced plan to restructure the Remediation and Construction Management (RCM) segment.
Sign-up for Tetra Tech Provides Update on RCM Segment Restructuring investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) today announced results for the fourth quarter and fiscal year ended September 28, 2014.
Sign-up for Tetra Tech Reports Fourth Quarter and Fiscal 2014 Results investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a $216 million indefinite delivery indefinite quantity contract from the U.S. Agency for International Development (USAID) to support the implementation of USAID’s program, the Promoting Gender Equity in National Priority Programs Project (PROMOTE) in Afghanistan.
Sign-up for Tetra Tech Wins $216 Million USAID Gender Equity Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year Indefinite Delivery-Indefinite Quantity, $30 million contract with the National Institute of Standards and Technology (NIST) to provide engineering services for the NIST Center for Neutron Research (NCNR). Tetra Tech will support the NCNR by providing world-class engineering services, including conceptual design/requirements analysis, and systems design and integration services to support upgrades for scientific instrumentation, procedures, and other NCNR components.
Sign-up for Tetra Tech Wins $30 Million NIST Engineering Services Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a $650 million multiple-award indefinite delivery indefinite quantity (IDIQ) contract by the U.S. Agency for International Development (USAID) to support the improvement of urban infrastructure in developing countries.
Sign-up for Tetra Tech Wins $650 Million USAID Urban Infrastructure Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year, $76 million contract with the U.S. Environmental Protection Agency (EPA) Region 4 to provide technical and advisory services to the Superfund Technical Assessment and Response Team (START IV). Tetra Tech will provide broad scientific and technical support services under START IV to assist the EPA in protecting human health and the environment in response to man-made and natural emergencies and disasters, and at polluted sites.
Sign-up for Tetra Tech Wins $76 Million U.S. EPA Superfund Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded three indefinite delivery indefinite quantity (IDIQ) contracts with the U.S. General Services Administration (GSA). The One Acquisition Solution for Integrated Services (OASIS) contracts are designed as vehicles to address all federal agencies’ needs for a full range of service requirements that integrate multiple professional service disciplines.
Sign-up for Tetra Tech Wins Three GSA OASIS Contracts investment picks
THE WOODLANDS, Texas , Nov.
Sign-up for TETRA Technologies, Inc. Announces Third Quarter 2014 Results And Updates 2014 Earnings Guidance investment picks
THE WOODLANDS, Texas , Oct.
Sign-up for TETRA Technologies, Inc. Announces Third Quarter 2014 Results Press Release And Conference Call Schedule investment picks
MALVERN, Pa., Nov.
Sign-up for TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B investment picks
MALVERN, Pa., Nov.
Sign-up for TetraLogic Pharmaceuticals to Host Investor Forum on November 10, 2014 investment picks
MALVERN, Pa., Dec.
Sign-up for TetraLogic to Participate in Two Conferences in December investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the closing of its underwritten public offering of 4,542,500 shares of common stock at an offering price of $19.00 per share.
Sign-up for Tetraphase Pharmaceuticals Announces Closing of Public Offering of Common Stock investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced initiation of patient enrollment in the pivotal portion of its IGNITE 2 Phase 3 clinical trial, a two-part trial studying the efficacy and safety of intravenous (IV) and oral formulations of eravacycline for the treatment of complicated urinary tract infections (cUTI). The company has selected the 200 mg eravacycline oral dose for the pivotal portion of the study after evaluating the positive results from the lead-in portion of the trial.
Sign-up for Tetraphase Pharmaceuticals Announces Initiation of Pivotal Portion of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that researchers will present a poster at IDWeek 2014 showing the preclinical activity of eravacycline, a novel tetracycline in late-stage clinical development, against several Gram-negative pathogens found in New York City—a city particularly plagued by multidrug-resistant (MDR) bacteria.
Sign-up for Tetraphase Pharmaceuticals Announces Presentation of Data at IDWEEK on the Activity of Eravacycline Against Multidrug-Resistant Bacteria investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it intends to offer and sell up to $75,000,000 of shares of its common stock in an underwritten public offering.
Sign-up for Tetraphase Pharmaceuticals Announces Proposed Public Offering of Common Stock investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results and key operating highlights for the third quarter ended September 30, 2014.
Sign-up for Tetraphase Pharmaceuticals Reports Third-Quarter 2014 Financial Results investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) , a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced its participation in two upcoming investor conferences: A live audio webcast of the Stifel presentation will be available on the Company's website at http://ir.tphase.com/events.cfm .
Sign-up for Tetraphase Pharmaceuticals to Participate in Upcoming Investor Conferences investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at BioCentury’s 2014 NewsMakers in the Biotech Industry Conference on Friday, September 26 th at 2:30 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at BioCentury’s 2014 NewsMakers in the Biotech Industry Conference investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at the Oppenheimer 25 th Annual Healthcare Conference on Thursday, December 11 at 1:00 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties (CEP-33237) as allowed for fast track designated products.
Sign-up for Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Launch of First Generic Celebrex® Capsules in the United States investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Launch of Generic Exforge HCT® Tablets in the United States investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas investment picks
2014/11/26
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Appoints Yitzhak Peterburg as Chairman investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Tetra Tech Announces Planned Dates for Fourth Quarter 2014 Results and Conference Call to Teva Appoints Yitzhak Peterburg as Chairman
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent